Watch List
Hello traders,
Last week we said our main plays were TXTM up (150%) and CEHC (up 90%)
I expect a much more exciting week this week as the OTC finally starts heating up again.
Last week we said our main plays were TXTM up (150%) and CEHC (up 90%)
I expect a much more exciting week this week as the OTC finally starts heating up again.
SAPX .0006 Seven Arts Entertainment
This is what I call free money,this stock has a triple bottom at .0006 with strong bid support on level 2 and has had several nice bounces from here recently also it has a amazing share structure
SAPX Security Details
Share Structure
| Market Value1 | $108,339 | a/o Sep 05, 2014 |
| Shares Outstanding | 180,564,252 | a/o Aug 25, 2014 |
| Float | Not Available | |
| Authorized Shares | 499,000,000 | a/o Aug 25, 2014 |
I feel very confident given the great chart and tiny SS we will see a easy 150% move and given the companies recent news http://finance.yahoo.com/news/seven-arts-entertainment-completes-acquisition-121500459.html of completing it's recent aquisitions we could even see the realllly big run very soon
FBEC .0007
Similar beauty setup like SAPX rock solid support right by the 52 week lows and a great share structure updated from their recently filed 10-Q which states "The number of shares outstanding of the Registrant’s Common Stock as of September 2, 2014 was 383,692,111.
Also according to recent PR's we should be seeing name change very soon with new company acquisitions definitely worth keeping a very close eye out on this one.
DKSC- .0013
If you've been following me you know ive been on this for a while awaiting for this sleeping giants over due news. After speaking with IR a few times and some other large investors in the company this is what I can tell you. The acquisitions, name change to Fotus, new video and website are now finally truly imminent. The delay was due to the time it took to get speak with all major investors to get over 50% shareholder approval for a increase in the A/S for the sole purpose of completing and funding these very key acquisitions. I am informed the votes are in, and this week the lawyer will be going over the papers and they will be filed. And then we will be getting what we've been waiting for. I am also informed from the IR that the current float is around 300 million shares.
The stock has held its support levels very strong and is now starting a Uptrendzz from the solid .0009 support. The last few days we've had solid support at .0011 and no selling. One thing I love about the stock is the level 2 has no bad MM's seems all retails and has proven in the past it can run fast and furious the time to get in here is fast approaching IMO.
Other stocks i'll we watching closely this week
INOH-Huge accumulations on this stock this past week and big rumors swirling around, watch for a breakout once it cracks the .00013's or on any news on the early lung cancer detection products.
TDCP-Great SS cutting edge tech has seen very solid consolidation and large buying at the .006 area look for a next leg up this week
CIHN-
CIHN put out huge news late (8:00) after hours on thursday not many people noticed it
and it is not on all the wires (otcmarkets.com) doesnt have it
http://money.cnn.com/news/
Plus stock is coming off 52 week low
and recently announced they cancelled 70 million shares bring o/s down
to 337 million
http://www.otcmarkets.com/
below is last nights press release
Caribbean International Holdings (CIHN) Announces Change in Control;
Seasoned Veteran in Stem Cell Industry Appointed as New CEO
Mark Farber MD, PhD, MS Received Degrees From Brown University and
SUNY; During His Time at Harvard Medical School He Developed
Bioreactor Designs for Stem Cell Based Tissue Engineered Heart Valves
September 04, 2014: 08:23 PM ET
Caribbean International Holdings (PINKSHEETS: CIHN) through its
subsidiary, Regenerative BioScience, Inc. ("RBS"), announced today
that on August 27, 2014, a private investment group, J3 Financial, has
acquired a controlling interest in the Company. Former CEO and former
controlling shareholder, Steven Swank has resigned as of that same
date; and effective as of August 28, 2014, the Company has appointed
Mark Farber MD, PhD, MS as the new CEO of CIHN.
A spokesperson for J3 stated that: "We had been tracking CIHN for some
time and found its business model very attractive. We feel that this
is a company that is ready to emerge and being able to acquire the
talents and services of someone like Dr. Farber, will help us
establish a sound foundation for future growth. We feel very lucky to
have him onboard."
The Company also said that it intends to identify, recruit and hire
additional industry professionals within the emerging stem cell
industry as it builds the infrastructure to support a solid but steady
growth. It will also be adding administrative and other veteran
executives in key positions.
The Company spokesperson also said that the Company feels it is
important in today's market to keep its shareholders fully abreast of
ongoing events and or news and it plans on keeping the market up to
date in order to remain fully transparent with the Company's current
and/or potential future shareholders and the market at large. In that
light, management of the Company will shortly be releasing a
Shareholder Update and other pertinent information as it becomes
available.
Below is a brief background and bio on the new CEO of CIHN, Mark
Farber, MD, PhD, MS.
Dr. Mark Farber received his undergraduate degree in Chemical
Engineering from Brown University in Providence, RI in 2001, followed
by a Masters in Science in Engineering from Brown University in 2003.
He received his MD/PhD combined degree from SUNY Downstate Medical
Center in Brooklyn, NY in 2013. His PhD project titled "Simultaneous
functional diffuse optical tomography and EEG in freely moving rats"
involved developing an emerging non-invasive optical imaging
technology to investigate brain blood flow in anesthetized, freely
foraging, and sleeping rats.
During the development of the diffuse optical tomography optical
imager, Dr. Farber's research generated over $7 million in grants,
including $130,000 from the competitive NIH Ruth Kirschstein National
Research Service Award for MD/PhD students from the NIH/NINDS. The
technology behind his PhD project for rat brain imaging was sold for
over $750,000, and with the assistance of Dr. Farber his technology
has been adapted for use in macaque research, clinical research, and
the development of brain-machine interfaces.
Prior to completing his education in medicine and engineering, Dr.
Farber spent three years working in developing stem cell bioreactors
for use in research and tissue engineering. After completing his MS in
Engineering, Dr. Farber briefly worked at ViaCell Inc. where he
developed bioreactors to maximize stem cell yields from umbilical cord
blood cultures. He then moved on to Harvard Medical School, where he
worked in the Cardiovascular Pathology department and participated in
research projects involving atherosclerosis, heart valve disease,
embryology, and tissue engineering. During this time he initiated
investigations into novel computerized methods of tissue collagen
detection and quantification and developed bioreactor designs for stem
cell based tissue engineered heart valves.
Dr. Farber has also worked at top immunology, cancer, and chemical
engineering labs in Brown University and National Institutes of Health
during his undergraduate education. He was also a lecturer in anatomy
and biostatistics at SUNY Downstate. Dr. Farber has over 17 years
experience in laboratory-based science and engineering research.
About The Company:
Caribbean International Holdings, Inc. is a holding company for
Regenerative Bio Science, Inc. ("RBSI"). The Company subsidiary RBSI
is focused on helping individuals protect and ensure their future
quality of life through Adult Stem Cell Incubation and the practice of
regenerative medicine in the United States and the Dominican Republic.
RBSI's mission is not only to allow patients to store their Stem Cells
for future use, but also perform patient funded stem cell therapies
from sports injuries to degenerative diseases such as MS, Arthritis,
Degenerative Heart Diseases, Diabetes and a host of experimental
therapies in the brain trauma disease sector including CTE. The goal
is to become a global leader in establishing protocols that can be
patented and utilized to heal patients around the world.
Adult stem cells work as the repairmen of the body by replenishing and
regenerating damaged tissues and cells. Certain conditions have shown
marked improvement when treated with adult stem cells taken from the
patient's own body. Regenerative BioScience is a revolution in
healthcare using a patient's own adult stem cells.
For more information go to: http://www.
CIHN put out huge news late (8:00) after hours on thursday not many people noticed it
and it is not on all the wires (otcmarkets.com) doesnt have it
http://money.cnn.com/news/
Plus stock is coming off 52 week low
and recently announced they cancelled 70 million shares bring o/s down
to 337 million
http://www.otcmarkets.com/
below is last nights press release
Caribbean International Holdings (CIHN) Announces Change in Control;
Seasoned Veteran in Stem Cell Industry Appointed as New CEO
Mark Farber MD, PhD, MS Received Degrees From Brown University and
SUNY; During His Time at Harvard Medical School He Developed
Bioreactor Designs for Stem Cell Based Tissue Engineered Heart Valves
September 04, 2014: 08:23 PM ET
Caribbean International Holdings (PINKSHEETS: CIHN) through its
subsidiary, Regenerative BioScience, Inc. ("RBS"), announced today
that on August 27, 2014, a private investment group, J3 Financial, has
acquired a controlling interest in the Company. Former CEO and former
controlling shareholder, Steven Swank has resigned as of that same
date; and effective as of August 28, 2014, the Company has appointed
Mark Farber MD, PhD, MS as the new CEO of CIHN.
A spokesperson for J3 stated that: "We had been tracking CIHN for some
time and found its business model very attractive. We feel that this
is a company that is ready to emerge and being able to acquire the
talents and services of someone like Dr. Farber, will help us
establish a sound foundation for future growth. We feel very lucky to
have him onboard."
The Company also said that it intends to identify, recruit and hire
additional industry professionals within the emerging stem cell
industry as it builds the infrastructure to support a solid but steady
growth. It will also be adding administrative and other veteran
executives in key positions.
The Company spokesperson also said that the Company feels it is
important in today's market to keep its shareholders fully abreast of
ongoing events and or news and it plans on keeping the market up to
date in order to remain fully transparent with the Company's current
and/or potential future shareholders and the market at large. In that
light, management of the Company will shortly be releasing a
Shareholder Update and other pertinent information as it becomes
available.
Below is a brief background and bio on the new CEO of CIHN, Mark
Farber, MD, PhD, MS.
Dr. Mark Farber received his undergraduate degree in Chemical
Engineering from Brown University in Providence, RI in 2001, followed
by a Masters in Science in Engineering from Brown University in 2003.
He received his MD/PhD combined degree from SUNY Downstate Medical
Center in Brooklyn, NY in 2013. His PhD project titled "Simultaneous
functional diffuse optical tomography and EEG in freely moving rats"
involved developing an emerging non-invasive optical imaging
technology to investigate brain blood flow in anesthetized, freely
foraging, and sleeping rats.
During the development of the diffuse optical tomography optical
imager, Dr. Farber's research generated over $7 million in grants,
including $130,000 from the competitive NIH Ruth Kirschstein National
Research Service Award for MD/PhD students from the NIH/NINDS. The
technology behind his PhD project for rat brain imaging was sold for
over $750,000, and with the assistance of Dr. Farber his technology
has been adapted for use in macaque research, clinical research, and
the development of brain-machine interfaces.
Prior to completing his education in medicine and engineering, Dr.
Farber spent three years working in developing stem cell bioreactors
for use in research and tissue engineering. After completing his MS in
Engineering, Dr. Farber briefly worked at ViaCell Inc. where he
developed bioreactors to maximize stem cell yields from umbilical cord
blood cultures. He then moved on to Harvard Medical School, where he
worked in the Cardiovascular Pathology department and participated in
research projects involving atherosclerosis, heart valve disease,
embryology, and tissue engineering. During this time he initiated
investigations into novel computerized methods of tissue collagen
detection and quantification and developed bioreactor designs for stem
cell based tissue engineered heart valves.
Dr. Farber has also worked at top immunology, cancer, and chemical
engineering labs in Brown University and National Institutes of Health
during his undergraduate education. He was also a lecturer in anatomy
and biostatistics at SUNY Downstate. Dr. Farber has over 17 years
experience in laboratory-based science and engineering research.
About The Company:
Caribbean International Holdings, Inc. is a holding company for
Regenerative Bio Science, Inc. ("RBSI"). The Company subsidiary RBSI
is focused on helping individuals protect and ensure their future
quality of life through Adult Stem Cell Incubation and the practice of
regenerative medicine in the United States and the Dominican Republic.
RBSI's mission is not only to allow patients to store their Stem Cells
for future use, but also perform patient funded stem cell therapies
from sports injuries to degenerative diseases such as MS, Arthritis,
Degenerative Heart Diseases, Diabetes and a host of experimental
therapies in the brain trauma disease sector including CTE. The goal
is to become a global leader in establishing protocols that can be
patented and utilized to heal patients around the world.
Adult stem cells work as the repairmen of the body by replenishing and
regenerating damaged tissues and cells. Certain conditions have shown
marked improvement when treated with adult stem cells taken from the
patient's own body. Regenerative BioScience is a revolution in
healthcare using a patient's own adult stem cells.
For more information go to: http://www.
